Hirayama, Ryuichiro
Toyohara, Kosuke
Watanabe, Kei
Otsuki, Takeya
Araoka, Toshikazu
Mae, Shin-Ichi
Horinouchi, Tomoko http://orcid.org/0000-0003-1655-6030
Yamamura, Tomohiko
Okita, Keisuke http://orcid.org/0000-0001-5806-1090
Hotta, Akitsu http://orcid.org/0000-0002-2619-7441
Iijima, Kazumoto
Nozu, Kandai
Osafune, Kenji http://orcid.org/0000-0001-7238-2763
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP23bm1123002, JP22bm0804013)
Article History
Received: 27 August 2022
Accepted: 2 August 2023
First Online: 28 September 2023
Competing interests
: R.H. is an employee of Taisho Pharmaceutical Co., Ltd. T.O. is an employee of Ono Pharmaceutical Co., Ltd. K. Osafune is a founder and member of the scientific advisory boards of iPS Portal, Inc., and a founder and chief scientific advisor of RegeNephro Co., Ltd. T.A. is a founder and scientific advisor of RegeNephro Co., Ltd. S.I.M. is a scientific advisor of RegeNephro Co., Ltd. R.H., T.A. and K. Osafune are the inventors of the iPSC-based disease model for AS (patent application 2021–184043). The other authors declare no competing interests.